WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock

$3.11-0.12 (-3.72%)
Updated May 22, 2024
GALT Price
$3.11
Fair Value Price
-$0.77
Market Cap
$193.28M
52 Week Low
$1.28
52 Week High
$4.27
P/E
-4.2x
P/B
-2.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$44.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.33
Operating Cash Flow
-$34M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GALT Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GALT ($3.11) is overvalued by 505.43% relative to our estimate of its Fair Value price of -$0.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GALT ($3.11) is not significantly undervalued (505.43%) relative to our estimate of its Fair Value price of -$0.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GALT due diligence checks available for Premium users.

Be the first to know about important GALT news, forecast changes, insider trades & much more!

GALT News

Valuation

GALT fair value

Fair Value of GALT stock based on Discounted Cash Flow (DCF)
Price
$3.11
Fair Value
-$0.77
Undervalued by
505.43%
GALT ($3.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GALT ($3.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GALT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.2x
Industry
9.89x
Market
31.29x

GALT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-2.65x
Industry
6.1x

GALT's financial health

Profit margin

Revenue
$0.0
Net Income
-$11.5M
Profit Margin
0%
GALT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$25.9M
Liabilities
$97.0M
Debt to equity
-1.33
GALT's short-term assets ($25.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GALT's long-term liabilities ($84.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GALT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.1M
Investing
$0.0
Financing
$10.0M
GALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GALT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GALT$193.28M-3.72%-4.20x-2.65x
ZVRA$193.78M+0.22%-3.43x3.97x
IVA$193.87M-2.36%-1.41x-5.57x
ATOS$192.41M-6.13%-6.38x2.24x
OPT$190.95M-3.54%-1.27x-32.62x

Galectin Therapeutics Stock FAQ

What is Galectin Therapeutics's quote symbol?

(NASDAQ: GALT) Galectin Therapeutics trades on the NASDAQ under the ticker symbol GALT. Galectin Therapeutics stock quotes can also be displayed as NASDAQ: GALT.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.

What is the 52 week high and low for Galectin Therapeutics (NASDAQ: GALT)?

(NASDAQ: GALT) Galectin Therapeutics's 52-week high was $4.27, and its 52-week low was $1.28. It is currently -27.13% from its 52-week high and 142.97% from its 52-week low.

How much is Galectin Therapeutics stock worth today?

(NASDAQ: GALT) Galectin Therapeutics currently has 62,148,134 outstanding shares. With Galectin Therapeutics stock trading at $3.11 per share, the total value of Galectin Therapeutics stock (market capitalization) is $193.28M.

Galectin Therapeutics stock was originally listed at a price of $12.00 in Sep 9, 2002. If you had invested in Galectin Therapeutics stock at $12.00, your return over the last 21 years would have been -74.08%, for an annualized return of -6.23% (not including any dividends or dividend reinvestments).

How much is Galectin Therapeutics's stock price per share?

(NASDAQ: GALT) Galectin Therapeutics stock price per share is $3.11 today (as of May 22, 2024).

What is Galectin Therapeutics's Market Cap?

(NASDAQ: GALT) Galectin Therapeutics's market cap is $193.28M, as of May 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Galectin Therapeutics's market cap is calculated by multiplying GALT's current stock price of $3.11 by GALT's total outstanding shares of 62,148,134.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.